Baidu
map

妇产科

订阅

MedSci主页 / 所有栏目 / 妇产科

HSD17B1抑制剂FOR-6219治疗子宫内膜异位症的Ib期试验已正式开始

2019-08-21 Allan MedSci原创

子宫内膜异位症HSD17B1FOR-6219
关注

Forendo是一家专注于女性健康的临床阶段药物开发公司，近日宣布HSD17B1抑制剂FOR-6219治疗子宫内膜异位症的Ib期试验已正式开始，目的是证明FOR-6219的作用机制。

Forendo是一家专注于女性健康的临床阶段药物开发公司，近日宣布HSD17B1抑制剂FOR-6219治疗子宫内膜异位症的Ib期试验已正式开始，目的是证明FOR-6219的作用机制。该新型口服化合物FOR-6219是一种HSD17B1抑制剂，旨在减少子宫内膜异位症病变局部的雌激素生成。参与该研究的第一批女性已经开始服用FOR-6219。

今年早些时候，Forendo已成功完成FOR-6219的第一次人类Ia期研究。在36名健康的绝经后妇女中，单剂量和多剂量的FOR-6219是安全的且耐受良好。FOR-6219的药代动力学与剂量成比例，并且在3天内达到稳态。观察到的消除半衰期约为16-18小时，展现了每日一次给药的可能性。

原始出处：

http://www.firstwordpharma.com/node/1660449#axzz5xBxiqv3r

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852101, encodeId=04a718521017b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Nov 06 13:23:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708542, encodeId=059b1e08542b4, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue May 05 19:23:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665659, encodeId=37191665659d1, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Sep 08 10:23:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940336, encodeId=dafd1940336ff, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Mar 17 11:23:00 CST 2020, time=2020-03-17, status=1, ipAttribution=)]
    2019-11-06 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1852101, encodeId=04a718521017b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Nov 06 13:23:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708542, encodeId=059b1e08542b4, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue May 05 19:23:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665659, encodeId=37191665659d1, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Sep 08 10:23:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940336, encodeId=dafd1940336ff, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Mar 17 11:23:00 CST 2020, time=2020-03-17, status=1, ipAttribution=)]
    2020-05-05 12498974m61暂无昵称

    #内膜#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1852101, encodeId=04a718521017b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Nov 06 13:23:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708542, encodeId=059b1e08542b4, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue May 05 19:23:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665659, encodeId=37191665659d1, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Sep 08 10:23:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940336, encodeId=dafd1940336ff, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Mar 17 11:23:00 CST 2020, time=2020-03-17, status=1, ipAttribution=)]
    2019-09-08 12498f17m74暂无昵称

    #子宫内膜异位#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1852101, encodeId=04a718521017b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Nov 06 13:23:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708542, encodeId=059b1e08542b4, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Tue May 05 19:23:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665659, encodeId=37191665659d1, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Sep 08 10:23:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940336, encodeId=dafd1940336ff, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Tue Mar 17 11:23:00 CST 2020, time=2020-03-17, status=1, ipAttribution=)]
    2020-03-17 bioon3

    #Ib期#

    0

相关资讯

喜大普奔！拜耳治疗子宫内膜异位症新药唯散宁®获批上市

5月13日，拜耳公司宣布，子宫内膜异位症治疗新药唯散宁®在华获批上市。唯散宁® 是含有2毫克的地诺孕素片剂，是一有效的、普遍耐受良好的子宫内膜异位症的治疗选择，它有效减轻疼痛、缩小病灶、降低术后复发率，可以长期安全使用，提高患者的生活质量，是专门为治疗子宫内膜异位症而研发的药物。子宫内膜异位症是子宫内膜生长在宫腔以外的部位。这种异位的组织也随月经周期而出血脱落。子宫内膜异位的常见部位是卵巢、子宫肌

研究发现巨噬细胞在子宫内膜异位症引起的疼痛中发挥重要调控作用

华威大学沃里克医学院Greaves实验室与爱丁堡大学的合作者一起，发现巨噬细胞在刺激神经细胞生长和活动的过程中发挥作用，导致骨盆疼痛。

子宫内膜异位症相关疼痛：GnRH受体拮抗剂linzagolix的II期试验取得成功

ObsEva是一家临床阶段的生物制药公司，致力于开发用于治疗女性生殖疾病的新疗法，ObsEva近日报道了IIb期EDELWEISS试验的后续结果，证明了口服促性腺激素释放激素（GnRH）受体拮抗剂linzagolix用于治疗子宫内膜异位症相关的骨盆疼痛的有效性。

Forendo Pharma成功完成FOR-6219的1a期临床试验，用于治疗子宫内膜异位症

子宫内膜异位症是一种慢性疾病，影响育龄10％的女性，并导致反复的疼痛症状、不孕和生活质量下降。目前可用的子宫内膜异位症治疗是进行全身性的雌激素耗竭，具有功效限制或副作用。FOR-6219仅抑制子宫内膜和子宫内膜异位病变中局部雌激素的生成，而不抑制女性全身雌激素水平。

Sunstone为芬兰女性健康公司Forendo Pharma投资500万欧元，用于资助子宫内膜异位症的临床研究

Sunstone Life Science Ventures宣布为专注于女性健康的新疗法公司Forendo Pharma投资500万欧元，用于资助Forendo Pharma将绝经后妇女进行的Ia期研究扩展到绝经前妇女的Ib期，以及IIc期用于治疗子宫内膜异位症的研究。

DNG可改善子宫内膜异位症患者的生活质量

子宫内膜异位症是一种常见的，慢性的，进行性的和复发性的疾病，影响患者的生活质量（QoL）。在dultsogest（DNG）每天2毫克在子宫内膜异位症中的安全性和有效性已在一些成人和青少年的临床研究中得到证实。这项前瞻性，非介入性，多中心研究调查了欧洲和中东11个国家213个研究点的成年人群中DNG的生活质量，安全性和有效性（n = 2866）。主要变量是在治疗6个月后表现出子宫内膜异位症健康问题5

Baidu
map
Baidu
map
Baidu
map